About
RNA Therapeutic Delivery technology
Areas of Focus
Categories
Drug Delivery & Formulation
Team (7)
Ed Yaworski
Chief Technology Officer
Genevant Sciences
executive
Gregg Ashby
Vice President of Finance
Genevant Sciences
executive
James Heyes, PhD
Chief Executive Officer
Genevant Sciences
executive
Kieu Lam
Vice President, Research
Genevant Sciences
executive
Pete Lutwyche, PhD
Executive Chair
Genevant Sciences
board_chair
Pete Zorn
GSI President and Chief Legal Officer
Genevant Sciences
executive
Clinical Trials (18)
View allTotal Trials
18
As Lead Sponsor
18
As Collaborator
0
Total Enrollment
2,333
By Phase
PHASE2: 13PHASE3: 5
By Status
RECRUITING: 8ACTIVE_NOT_RECRUITING: 5TERMINATED: 2COMPLETED: 2ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline18 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07188844Lead Sponsor
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PHASE2Enrolling by invitation
108 participants
Started: Aug 28, 2025 · Completed: Nov 30, 2028
NCT06979531Lead Sponsor
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
PHASE2Recruiting
180 participants
Started: Jun 30, 2025 · Completed: Jul 31, 2028
NCT07018323Lead Sponsor
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
PHASE2Recruiting
210 participants
Started: Jun 19, 2025 · Completed: May 31, 2027
NCT07039916Lead Sponsor
Study to Access the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
PHASE3Recruiting
231 participants
Started: May 27, 2025 · Completed: Dec 31, 2027
NCT07032662Lead Sponsor
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PHASE2Recruiting
162 participants
Started: Mar 18, 2025 · Completed: May 31, 2030
Locations (1)
Headquarters
Vancouver, BC, Canada
Map
Loading map...